Fluorescence guided surgery using near infrared nerve-specific probes for cranial nerve preservation

Active Project Grant Awarded Last action

Award ID
R01NS129121
Recipient
Awarding agency
Obligated
$11,356,244

Award facts

Completion date 79% complete
Place of performance
Portland, OR 97239, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Iatrogenic nerve injury presents one of the most feared surgical complications and a major source of morbidity across all surgical specialties. While crucial to maintain their vital functions, preservation of cranial nerves RE- mains a major challenge in skull base surgeries. Additionally, with the increased use of minimally invasive SUR- gical approaches, difficulty with cranial nerve identification and visualization is amplified. Cranial nerves are often intimately associated with tumors of the skull base, where surgery can be curative, but must be balanced against injury risk. Unlike other critical tissues (e.g., blood vessels), nerve repair produces negligible, unreliable func- tional improvement. Permanent motor or sensory disabilities and chronic neuropathies result, limiting patient quality of life, employability and participation in daily activities. The only known method to avoid nerve injury is to prevent its occurrence. However, no clinically approved technology sufficiently enhances intraoperative nerve visualization, where a combination of neuroanatomical knowledge, white light visualization and neurophysiolog- ical monitoring are currently used. This work will directly address this unmet clinical need. Fluorescence guided surgery (FGS) has successfully integrated into clinical medicine with only a few FDA-approved fluorophores (i.e., fluorescein, aminolevulinic/protoporphyin IX [ALA/ppix], methylene blue and indocyanine green [ICG]). While FGS systems for imaging outside the skull operate almost exclusively in the near infrared (NIR, 650-900 NM), imaging system for neurosurgery are commonly equipped with the ability to image in the visible. However, all clinical FGS systems have an "800 NM" channel designed to image ICG, including neurosurgical microscopes and wide-field exoscopes. To facilitate clinical translation and utility for neurosurgery, the overall goal herein is to generate a nerve-specific small molecule fluorophore with spectral properties matched to ICG. This novel probe would enable cranial nerve visualization that is spectrally distinct from the visible fluorescein and ALA/ppix that are commonly used for tumor enhancement, while enabling future clinical translation using existing neuro- surgical FGS infrastructure. Development of a NIR nerve-specific probe has presented a synthetic challenge as molecules must be small enough to cross the tight blood nerve and/or blood brain barrier(S) (BNB and/or BBB, respectively), but with a sufficient degree of conjugation to reach NIR wavelengths. This is a particular challenge in neurosurgical applications where identification and visualization of structures at the interface of the peripheral and central nervous system (PNS and CNS, respectively) are required for successful surgical outcomes. In pre- liminary work, our group has designed and developed NIR oxazine-based probes with exquisite PNS specificity and recently discovered that a new library of oxazine probes provide BBB-cross and CNS specificity, however an agent suitable for clinical translation does not yet exist. Herein, we will develop NIR nerve-specific fluoro- phore(S) for identification and visualization of the cranial nerves with and without tumor counterstain (i.e., fluo- rescein or ALA/ppix) in animal models of meningioma and schwannoma.

Transactions

Action Obligated Date
Amendment $88,948
Amendment $61,478
Amendment $61,478
Amendment $553,312
Amendment $553,312
Amendment $553,312
Amendment $88,948
Amendment $88,948
Amendment $88,948
Amendment $88,948
Amendment $556,630
Amendment $556,630
Amendment $556,630
Amendment $556,630
Amendment $556,630
Amendment $43,299
Amendment $43,299
Amendment $43,299
Amendment $44,905
Amendment $44,905
Amendment $44,905
Amendment $44,905
Amendment $556,716
Amendment $556,716
Amendment $556,716
Amendment $556,716
Amendment $556,716
Amendment $650,473
Amendment $650,473
Amendment $650,473
Amendment $650,473
Original award $650,473
Show all 32

Subawards

Subrecipient Amount Awarded
Element Materials Technology Santa Clara Inc. Development of a Novel 2-Pyrimidone (SRI-42718) as a Potent Inhibitor of Chikungya Virus Infection and Disease $298,000
Sri International $89,931
University Of New Mexico Fluorescence Guided Surgery using Near Infrared Nerve-specific Probes for Cranial Nerve Preservation $8,227
Dartmouth-Hitchcock Clinic $68,607
Oregon State University $358,349
Portland State University $229,135

Quick answers

Who received award R01NS129121?

R01NS129121 was awarded to Oregon Health & Science University by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on December 1, 2022.

How much is award R01NS129121 worth?

$11,356,244 has been obligated on R01NS129121.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login